OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.95
−0.34%0
Insider buys (3m)
2
Insider sells (3m)
-$1.7K
Net value (3m)
-32.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 11, 2026 | Leverone Jason A. · officer: Chief Financial Officer | A-Award | 130,611 | $4.14 |
| Aug 11, 2026 | Hartley Dylan · officer: Chief Scientific Officer | A-Award | 50,000 | $4.14 |
| Aug 11, 2026 | Leverone Jason A. · officer: Chief Financial Officer | A-Award | 5,322 | $4.14 |
| Aug 11, 2026 | Carruthers R Michael · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 150,000 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 2,359 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 1,485 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 8,449 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 16,898 | $4.14 |
| Aug 11, 2026 | Saccomano Nicholas A · director, officer: President and CEO | A-Award | 542,232 | $4.14 |
| Aug 11, 2026 | Leverone Jason A. · officer: Chief Financial Officer | A-Award | 50,000 | $4.14 |
| Aug 11, 2026 | Leverone Jason A. · officer: Chief Financial Officer | A-Award | 5,781 | $4.14 |
| Aug 11, 2026 | GREY MICHAEL G · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Jansen Valerie Malyvanh · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Manke Isaac · director | A-Award | 15,300 | $4.14 |
| Aug 11, 2026 | Manke Isaac · director | A-Award | 300,000 | $4.14 |
| Aug 11, 2026 | Phillips Andrew John · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Ratcliffe Liam · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Mathers Edward T · director | A-Award | 22,350 | $4.14 |
| Aug 11, 2026 | Agresta Samuel · officer: Chief Medical Officer | A-Award | 131,396 | $4.14 |
| Aug 11, 2026 | Agresta Samuel · officer: Chief Medical Officer | A-Award | 18,588 | $4.14 |
| Aug 11, 2026 | Agresta Samuel · officer: Chief Medical Officer | A-Award | 50,000 | $4.14 |
| Aug 11, 2026 | Hartley Dylan · officer: Chief Scientific Officer | A-Award | 137,603 | $4.14 |
| Jun 24, 2026 | Saccomano Nicholas A · director, officer: President and CEO | Sale | 86 | $4.40 |
| Jun 24, 2026 | Leverone Jason A. · officer: Chief Financial Officer | Sale | 303 | $4.40 |
| Jun 8, 2026 | Ratcliffe Liam · director | A-Award | 1,275 | $4.30 |
| Jun 8, 2026 | Carruthers R Michael · director | A-Award | 7,650 | $4.30 |
| Jun 8, 2026 | GREY MICHAEL G · director | A-Award | 7,650 | $4.30 |
| Jun 8, 2026 | Jansen Valerie Malyvanh · director | A-Award | 7,650 | $4.30 |
| Jun 8, 2026 | Phillips Andrew John · director | A-Award | 7,650 | $4.30 |
Institutional positioning
13F filings over the trailing two quarters
New 50Increased 33Reduced 23Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 3,998,333 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 3,998,333 | May 15, 2026 |
| BVF INC/IL | Increased | 3,235,778 | Aug 14, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Unchanged | 2,839,674 | May 15, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Unchanged | 2,839,674 | Aug 14, 2026 |
| StepStone Group LP | Unchanged | 2,660,612 | Aug 13, 2026 |
| STEPSTONE GROUP LP | Increased | 2,660,612 | May 15, 2026 |
| ADAR1 CAPITAL MANAGEMENT, LLC | Increased | 2,434,941 | May 18, 2026 |
| ADAR1 Capital Management, LLC | Reduced | 2,238,684 | Aug 14, 2026 |
| PROSIGHT MANAGEMENT, LP | Increased | 2,154,381 | May 15, 2026 |
| BVF INC/IL | New Position | 1,978,972 | May 15, 2026 |
| VIVO CAPITAL, LLC | New Position | 1,927,710 | May 20, 2026 |
| Vivo Capital, LLC | Unchanged | 1,927,710 | Aug 14, 2026 |
| VESTAL POINT CAPITAL, LP | Increased | 1,839,819 | May 15, 2026 |
| Vestal Point Capital, LP | Reduced | 1,825,699 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 11, 2026